COURAGE Suggests Stents Do Not Benefit Stable Coronary Disease Patients
Results of the highly anticipated COURAGE trial challenge the widespread assumption that stents improve outcomes in patients with stable coronary disease, but several observers believe the findings' impact on the stent market will be modest
More from Archive
More from Medtech Insight
Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.
In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.
Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.